- Home
- NRGV vs CLLS Comparison
NRGV vs CLLS Comparison
Compare NRGV & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NRGV | CLLS |
|---|---|---|
| Founded | 2017 | 1999 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 785.5M | 394.4M |
| IPO Year | 2021 | 2014 |
Fundamental Metrics
Financial Performance| Metric | NRGV | CLLS |
|---|---|---|
| Price | $4.24 | $1.46 |
| Analyst Decision | Strong Sell | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $2.00 | ★ $8.33 |
| AVG Volume (30 Days) | ★ 3.2M | 117.1K |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 28.57 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $203,671,000.00 | N/A |
| Revenue This Year | $28.93 | N/A |
| Revenue Next Year | $16.69 | $0.98 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 340.86 | N/A |
| 52 Week Low | $2.11 | $2.35 |
| 52 Week High | $6.65 | $5.48 |
Technical Indicators
Market Signals| Indicator | NRGV | CLLS |
|---|---|---|
| Relative Strength Index (RSI) | 54.36 | 17.47 |
| Support Level | $3.68 | N/A |
| Resistance Level | $4.11 | $3.47 |
| Average True Range (ATR) | 0.27 | 0.22 |
| MACD | 0.03 | -0.22 |
| Stochastic Oscillator | 65.23 | 5.96 |
Price Performance
Historical ComparisonAbout NRGV Energy Vault Holdings Inc.
Energy Vault Holdings Inc is a diversified portfolio of energy storage solutions to third parties, including proprietary gravity, battery, and green hydrogen-based technologies, supported by technology-agnostic energy management software and integration capabilities. Geographical presence in the United States, Australia, and other countries. The majority of its revenue comes from Australia.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.